RxSight, Inc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| RxSight, Inc. | ||
| Date: February 25, 2026 | By: | /s/ Ron Kurtz, M.D. |
|---|---|---|
| Ron Kurtz, M.D. | ||
| President and Chief Executive Officer | ||
| (Principal Executive Officer) | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Ron Kurtz, M.D. and Mark Wilterding as such individual’s true and lawful attorney in fact and agent with full power of substitution, for such individual in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney in fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney in fact, proxy and agent, or the individual’s substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Ron Kurtz, M.D. | President and Chief Executive Officer and Director | February 25, 2026 |
| Ron Kurtz, M.D. | (Principal Executive Officer) | |
| /s/ Mark Wilterding | Chief Financial Officer | February 25, 2026 |
| Mark Wilterding | (Principal Financial and Accounting Officer) | |
| /s/ J. Andy Corley | Chairman of the Board | February 25, 2026 |
| J. Andy Corley | ||
| /s/ William Link, Ph.D. | Director | February 25, 2026 |
| William Link, Ph.D. | ||
| /s/ Juliet Tammenoms Bakker | Director | February 25, 2026 |
| Juliet Tammenoms Bakker | ||
| /s/ Julie Andrews | Director | February 25, 2026 |
| Julie Andrews | ||
| /s/ Robert Palmisano | Director | February 25, 2026 |
| Robert Palmisano | ||
| /s/ Robert Warner | Director | February 25, 2026 |
| Robert Warner | ||
| /s/ Shweta Singh Maniar | Director | February 25, 2026 |
| Shweta Singh Maniar | ||
| /s/ Tamara R. Fountain, M.D. | Director | February 25, 2026 |
| Tamara R. Fountain, M.D. | ||
| /s/ Raymond W. Cohen | Director | February 25, 2026 |
|---|---|---|
| Raymond W. Cohen | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.